Gene editing and modulation for Duchenne muscular dystrophy.

Area of Science:

• Biomedical research
• Genetic medicine
• Neuromuscular disorders

Background:

• Duchenne muscular dystrophy (DMD) is a fatal genetic disorder caused by DMD gene mutations leading to dystrophin deficiency.
• DMD causes progressive muscle degeneration, loss of ambulation, and premature death.
• Current gene therapies show promise but face challenges in durability and efficacy.

Purpose of the Study:

• To review advancements in gene editing and modulation therapies for DMD.
• To highlight experimental DMD therapies nearing clinical application.
• To discuss barriers and unanswered questions in DMD gene therapy.

Main Methods:

• Review of current literature on gene editing and modulation strategies for DMD.
• Analysis of emerging experimental therapies and their progress toward clinical trials.
• Evaluation of safety and efficacy data for novel DMD treatments.

Main Results:

• First-generation gene therapies (gene replacement, splicing modulation) are in clinical trials.
• Somatic cell gene editing represents a promising next-generation therapeutic approach for DMD.
• Ongoing research focuses on improving durability, safety, and translatable efficacy of DMD therapies.

Conclusions:

• Gene editing and modulation therapies are rapidly advancing the treatment landscape for Duchenne muscular dystrophy.
• Further research is crucial to address safety and efficacy for successful clinical translation.
• These innovative approaches hold significant potential for improving outcomes in DMD patients.